Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Home
Current IssueAccepted ManuscriptsAll IssuesIn Press ArticlesSearch
Instructions
Journal InformationBoards and committeesIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Crossref

1. New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)

- Payam Peymani

- Behzad Yeganeh

- Siamak Sabour

- Bita Geramizadeh

- Mohammad Reza Fattahi

- Hossein Keyvani

- Negar Azarpira

- Kevin M. Coombs

- Saied Ghavami

- Kamran B. Lankarani

2. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals

- Khashayar Hesamizadeh

- Heidar Sharafi

- Mohammad Saeid Rezaee-Zavareh

- Bita Behnava

- Seyed Moayed Alavian

3. A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran

- Mojtaba Jafari

- Parisa Mehdizadeh

- Khosro Keshavarz

- Ehsan Teymourzadeh

- Mohammad Ali Abyazi

- Seyed Moayed Alavian

- Alijanpour Pouria

4. Occult HCV Infection: The Current State of Knowledge

- Mohammad Saeid Rezaee-Zavareh

- Reza Hadi

- Hamidreza Karimi-Sari

- Mohammad Hossein Khosravi

- Reza Ajudani

- Fardin Dolatimehr

- Mahdi Ramezani-Binabaj

- Seyyed Mohammad Miri

- Seyed Moayed Alavian

5. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection

- Seyed Moayed Alavian

- Shekoufeh Nikfar

- Abbas Kebriaeezadeh

- Farhad Lotfi

- Ehsan Sanati

- Mohsen Rezaei Hemami

- Khosro Keshavarz

6. Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review

- Mojtaba Jafari

- Parisa Mehdizadeh

- Ehsan Teymourzadeh

- Mahmood Salesi

- Khosro Keshavarz

- Mohammad Ali Abyazi

- Mohammad Heiat

- Seyed Moayed Alavian

7. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C

- Zahra Goudarzi

- Abdollah Poursamad

- Iman Karimzadeh

- Nahid Jallaly

- Khosro Keshavarz

- Seyed Moayed Alavian

8. Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study

- Mojtaba Jafari

- Parisa Mehdizadeh

- Khosro Keshavarz

- Ehsan Teymourzadeh

- Mohammad Ali Abyazi

- Parsa Gholamreza Shirazi